Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

BACKGROUND: Src, an oncoprotein that drives progression of head and neck squamous cell carcinoma (HNSCC), is commonly hyperactivated in this disease. Unfortunately, the clinical benefit of targeting Src is significantly dampened in HNSCC patients, because the cytotoxic effects of anti-Src therapy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Liwei, Shay, Chloe, Zhao, Xiangdong, Xiong, Yuanping, Wang, Xuli, Teng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896687/
https://www.ncbi.nlm.nih.gov/pubmed/31805962
http://dx.doi.org/10.1186/s13045-019-0827-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896687/
https://www.ncbi.nlm.nih.gov/pubmed/31805962
http://dx.doi.org/10.1186/s13045-019-0827-1

Ejemplares similares